MedTrace Logo

LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

NCT04053062 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-01-05

No results posted yet for this study

Summary

This is a single center, single arm Phase I study to establish the safety and efficacy of intravenously administered lentivirally transduced LIGHT-PSMA-specific CAR modified autologous T cells (PSMA-CART cells) in patients with CRPC.

Conditions

  • Castrate-Resistant Prostate Cancer

Interventions

BIOLOGICAL

LIGHT-PSMA-CART cells

LIGHT-PSMA-CART cells will be given IV at split doses

Sponsors & Collaborators

  • Changhai Hospital

    collaborator OTHER

  • Bioray Laboratories

    lead INDUSTRY

Principal Investigators

  • Shancheng Ren, Professor · Changhai Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-16
Primary Completion
2022-05-15
Completion
2024-10-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04053062 on ClinicalTrials.gov